Enhancing pediatric access to cell and gene therapies
Document Type
Journal Article
Publication Date
7-1-2024
Journal
Nature medicine
Volume
30
Issue
7
DOI
10.1038/s41591-024-03035-1
Abstract
Increasing numbers of cell and gene therapies (CGTs) are emerging to treat and cure pediatric diseases. However, small market sizes limit the potential return on investment within the traditional biopharmaceutical drug development model, leading to a market failure. In this Perspective, we discuss major factors contributing to this failure, including high manufacturing costs, regulatory challenges, and licensing practices that do not incorporate pediatric development milestones, as well as potential solutions. We propose the creation of a new entity, the Pediatric Advanced Medicines Biotech, to lead late-stage development and commercialize pediatric CGTs outside the traditional biopharmaceutical model in the United States-where organized efforts to solve this problem have been lacking. The Pediatric Advanced Medicines Biotech would partner with the academic ecosystem, manufacture products in academic good manufacturing practice facilities and work closely with regulatory bodies, to ferry CGTs across the drug development 'valley of death' and, ultimately, increase access to lifesaving treatments for children in need.
APA Citation
Mackall, Crystal L.; Bollard, Catherine M.; Goodman, Nancy; Carr, Casey; Gardner, Rebecca; Rouce, Rayne; Sotillo, Elena; Stoner, Rich; Urnov, Fyodor D.; Wayne, Alan S.; Park, Julie; and Kohn, Donald B., "Enhancing pediatric access to cell and gene therapies" (2024). GW Authored Works. Paper 5372.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/5372
Department
Pediatrics